Global Biosimilar Market: FDA and EMA Trends

This global biosimilar market analysis: trends and challenges piece focuses on what regulators actually changed. FDA is streamlining comparative efficacy and interchangeability expectations, while EMA’s biosimilar medicines pathway remains a separate EU standard that BD and market-access teams must plan for explicitly.

Key Takeaways

FDA draft guidance aims to cut low-sensitivity comparative efficacy studies that the agency said can take 1–3 years and cost about $24 million on average.
FDA now generally does not recommend switching studies solely to support interchangeability designations.
March 2026 Revision 4 Q&A draft updates use of non–U.S.-licensed comparators and related pharmacokinetic study expectations under the BPCI Act.
EMA’s biosimilar overview remains the EU reference frame; global launches still require dual-region regulatory strategy.

What is driving change in the global biosimilar market?

Payers and health systems want lower-cost biologics, but development cost and uncertain interchangeability rules have slowed entry. FDA’s 2025–2026 communications argue that analytical methods now often outperform large comparative efficacy trials for detecting meaningful product differences, so clinical burden should fall when science supports it.

Primary: FDA announcement on accelerating biosimilar development.

How is FDA rewriting comparative efficacy expectations?

In draft guidance on scientific considerations for biosimilarity, FDA describes when a comparative efficacy study (CES) may not be necessary if comparative analytical assessment, pharmacokinetic similarity, and immunogenicity data adequately address clinically meaningful differences. The agency also noted it withdrew the April 2015 “Scientific Considerations” final guidance because thinking has evolved since the first U.S. biosimilar approval in 2015.

For BD diligence, treat this as draft policy until finalized. Sponsors still need totality-of-evidence packages under section 351(k) of the Public Health Service Act.

What did Revision 4 of the biosimilar Q&As change?

FDA’s March 2026 draft “New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 4)” updates recommendations on using non–U.S.-licensed comparator products. In some scenarios, FDA says applicants may rely on outside-U.S. clinical comparator data without an additional three-way pharmacokinetic study, if scientifically justified.

Source: FDA announcement on further biosimilar streamlining steps and the linked Revision 4 draft Q&A page.

How does EMA’s biosimilar pathway differ for EU launches?

EMA publishes a dedicated biosimilar medicines overview explaining the EU regulatory concept: highly similar quality, safety, and efficacy to an already authorized reference biological medicine, with an abbreviated clinical package relative to a full new biologic—but not identical to FDA’s interchangeability construct.

EU: centralized EMA assessment against an EU reference product
U.S.: 351(k) biosimilarity vs a U.S.-licensed reference, with optional interchangeability
Practical gap: pharmacy substitution rules and naming conventions still differ by jurisdiction

EU frame: EMA biosimilar medicines overview.

What challenges still constrain biosimilar market entry?

Even if clinical trial burden falls, companies still face manufacturing scale-up, patent and exclusivity thickets, tendering dynamics in Europe, and U.S. rebate wall / formulary contracting. Interchangeability without switching studies may speed designations, but state pharmacy law and payer preference protocols still gate automatic substitution.

Pipeline “wins” only matter when paired with a clear reference-product LOE date and a channel plan. Vague claims about Amgen or Sandoz market share without filings or tenders are not useful diligence.

What should investors track beyond regulatory drafts?

Global Biosimilar Market Analysis: Trends and Challenges is ultimately a capital-allocation problem. Watch reference-product loss-of-exclusivity calendars, manufacturing capacity for large molecules, and tender outcomes in major EU markets. Regulatory streamlining can compress development timelines, but it does not remove patent litigation or rebate contracting as gating items.

When FDA finalizes CES and interchangeability recommendations, update internal probability-of-success assumptions for mid-stage biosimilar portfolios. Until finalization, keep a sensitivity case that still budgets a CES for complex or immunogenic reference products where FDA may still want clinical data.

What remains unproven?

This article does not assert a single global market size, CAGR, or 2026 revenue figure because those numbers were not sourced from an allowlisted primary dataset here. Draft FDA guidances are not final rules. EMA overview pages also do not quantify U.S. interchangeability outcomes. Delete speculative “arms race” framing that cannot be evidenced.

Related NovaPharma coverage

Frequently Asked Questions

How is the FDA changing biosimilar development expectations?

FDA has issued draft guidance to reduce unnecessary comparative efficacy studies when analytical, pharmacokinetic, and immunogenicity data can support biosimilarity, and it generally no longer recommends switching studies solely to support interchangeability.

Do U.S. and EU biosimilar pathways match?

No. EMA maintains a distinct EU biosimilar medicines framework under EU pharmaceutical law, while FDA regulates biosimilars under the BPCI Act pathway (351(k)). Sponsors still need region-specific dossiers even when analytical packages overlap.

What should BD teams treat as unproven in biosimilar market forecasts?

Do not treat draft FDA guidance as final rules, and do not invent global market-size CAGR figures without a primary dataset. Interchangeability policy shifts also do not automatically equal pharmacy substitution in every U.S. state.